|1.||Tack, K: 4 articles (03/2002 - 01/2001)|
|2.||Trostmann, U: 3 articles (03/2002 - 01/2001)|
|3.||Welling, L: 2 articles (01/2002 - 01/2001)|
|4.||Eiseman, I: 2 articles (09/2001 - 02/2001)|
|5.||Tack, K J: 2 articles (02/2001 - 02/2001)|
|6.||Bagga, Arvind: 1 article (04/2009)|
|7.||Dharmaraj, Rajmohan: 1 article (04/2009)|
|8.||Hari, Pankaj: 1 article (04/2009)|
|9.||Levine, Donald P: 1 article (03/2004)|
|10.||Holley, H Preston: 1 article (03/2004)|
03/01/2002 - "Considering that most of the patients had several infections caused by multiply resistant pathogens, clinafloxacin may be useful for the treatment of such life-threatening episodes."
01/01/2001 - "The results of this study clearly demonstrate the safety and efficacy of clinafloxacin in the treatment of a range of intraabdominal infections, and in patients with a broad range of physiologic disturbances."
03/01/2002 - "Open-label, multicentre, emergency-use study of clinafloxacin (CI-960) in the treatment of patients with serious life-threatening infections."
01/01/2001 - "The objectives of this study are to evaluate the pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections and to describe our experience with mixed-effects modelling using heterogeneous pharmacokinetic data. "
01/01/2001 - "Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: experience with heterogeneous pharmacokinetic data."
|2.||Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis)
04/01/2000 - "Comparative therapeutic efficacy of clinafloxacin in a pneumococcal meningitis mouse model."
01/01/2003 - "Experimental study of clinafloxacin alone and in combination in the treatment of ciprofloxacin-susceptible and -resistant pneumococcal meningitis."
04/01/2000 - "The therapeutic efficacy of clinafloxacin, a fluoroquinolone in clinical trials, was compared with that of ciprofloxacin and ceftriaxone in a novel pneumococcal meningitis mouse model. "
01/01/2003 - "The aim of the present study was to determine the efficacy of clinafloxacin alone and in combination with teicoplanin and rifampin in the therapy of ciprofloxacin-susceptible and ciprofloxacin-resistant pneumococcal meningitis in rabbits. "
03/01/1998 - "A deep-seated Pseudomonas aeruginosa mouse kidney abscess model was used to compare the therapeutic efficacy of clinafloxacin, a fluoroquinolone in clinical trials, with that of clinically relevant standard drugs. "
03/01/1998 - "Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model."
05/01/1993 - "Therapy with ofloxacin, ciprofloxacin, and lomefloxacin (alone or in combination with clindamycin) and therapy with sparfloxacin, clinafloxacin, and temafloxacin alone were given to mice with subcutaneous abscesses. "
|4.||Respiratory Tract Infections (Respiratory Tract Infection)
01/01/1999 - "These site concentrations exceeded the MIC90 for common respiratory pathogens and indicate that clinafloxacin is likely to be effective in the treatment of a wide range of respiratory tract infections."
11/01/1998 - "The activities of six new fluoroquinolones (moxifloxacin, grepafloxacin, gatifloxacin, trovafloxacin, clinafloxacin, and levofloxacin) compared with those of sparfloxacin and ciprofloxacin with or without reserpine (20 microg/ml) were determined for 19 Streptococcus pneumoniae isolates, 5 Haemophilus sp. isolates, and 10 Pseudomonas aeruginosa isolates with decreased susceptibility to ciprofloxacin from patients with clinically confirmed lower respiratory tract infections. "
|5.||Listeriosis (Listeria Infection)
10/01/1997 - "Clinafloxacin (CL 960) is superior to standard therapeutics in the treatment of murine listeriosis and salmonellosis."
01/01/1997 - "We conclude that clinafloxacin, levofloxacin, or sparfloxacin could represent a therapeutic alternative to amoxicillin for the treatment of Listeria infections in adults, especially clinafloxacin, whose MIC is low (0.06 to 0.12 micrograms/ml), and whose best activity against intracellular L. "
|7.||Anti-Infective Agents (Microbicides)
|10.||sparfloxacin (AT 4140)